Avience targets January 2027 YEIDA analyzer commissioning
Key highlights
- Avience targets January 2027 commissioning of a Rs 30.18 crore automated biochemistry-analyzer factory at YEIDA.
- The proposed YEIDA site covers 2,100 square metres at Plot No. 70, Sector 28.
- The funding mix comprises Rs 15.95 crore in IPO proceeds, Rs 12 crore in SIDBI funding and Rs 2.23 crore in internal accruals.
- Avience reports 117 CDSCO manufacturing licenses and more than 200 products under approval.
powered by IRIS

Avience Biomedicals Limited targets January 2027 commissioning of a Rs 30.18 crore fully automated biochemistry-analyzer factory at YEIDA Medical Device Park in Gautam Buddha Nagar, Uttar Pradesh. The proposed 2,100-square-metre facility has a disclosed funding mix of Rs 15.95 crore in IPO proceeds, Rs 12 crore in SIDBI funding and Rs 2.23 crore in internal accruals.
Know Avience Biomedicals inside out
Results, valuation, peers and who's buying, in one view.
What is Avience building at YEIDA Medical Device Park?
Avience is planning a fully automated manufacturing facility focused on biochemistry analyzers at Plot No. 70, Sector 28, YEIDA Medical Device Park. The presentation specifies a 2,100-square-metre land area in Gautam Buddha Nagar, Uttar Pradesh, and identifies January 2027 as the target commissioning date.
The proposed factory is part of Avience's stated growth phase from 2026 onward, which includes a fully automated Medical Device Park facility and capacity expansion across product categories. This is more specific than the earlier milestones listed in its timeline: incorporation on 23 December 2019, product-portfolio expansion in 2020, manufacturing expansion in 2022 and conversion to a public limited company in 2024.
Avience lists Avience Biochemistry among its manufactured products, along with rapid test kits, molecular products, culture media, oxygen concentrators, electrolyte analyzers and haematology analyzers. The YEIDA project's stated focus is narrower than that wider range because it is designated for biochemistry-analyzer manufacturing rather than every diagnostic category.
How will Avience fund the Rs 30.18 crore project?
Avience plans to fund the Rs 30.18 crore project through Rs 15.95 crore of IPO proceeds, Rs 12 crore of SIDBI funding and Rs 2.23 crore of internal accruals. IPO proceeds are the largest single disclosed source, while the three components total the stated project investment.
The IPO-proceeds and SIDBI components together amount to Rs 27.95 crore, compared with Rs 2.23 crore from internal accruals. The presentation does not disclose the interest rate, repayment terms, security, drawdown schedule or conditions associated with the Rs 12 crore SIDBI funding.
The Rs 30.18 crore figure is presented as total project investment, rather than revenue, profit or annual operating expenditure. Avience does not provide a split between land, construction, machinery, automation equipment, regulatory expenditure, working capital or other costs.
Got a follow-up? Ask IRIS
What capability is Avience adding through the new factory?
Avience says the YEIDA factory is intended to create dedicated biochemistry-analyzer manufacturing capability in a fully automated facility. Its stated objectives include expanding manufacturing infrastructure, increasing production capacity, supporting product diversification and strengthening its presence in medical devices.
The product ecosystem classifies analyzers as diagnostic instruments, alongside electrolyte systems and automated diagnostic equipment. It separately lists biochemistry reagents under reagents, while other segments include in-vitro diagnostic, or IVD, kits, medical consumables, molecular diagnostics and healthcare solutions.
Management lists higher manufacturing scale, improved operational efficiency, domestic and export potential, and service to hospitals, laboratories and research institutions as expected benefits. These are expected outcomes rather than reported results because Avience gives no projected unit output, revenue contribution, export volume, margin change or capacity-utilisation target for the January 2027 facility.
Avience also reports 43 Central Drugs Standard Control Organisation, or CDSCO, manufacturing licenses for biochemistry products, including biochemistry analyzers, reagents, electrolyte analyzers, consumables and collection tubes. Across four diagnostic segments, it reports 117 CDSCO manufacturing licenses and says applications are under process for more than 200 additional products, without linking particular applications to YEIDA.
What approvals and execution points should readers track?
Avience describes a nine-stage CDSCO manufacturing-license process with an average timeline of 9 to 12 months. The sequence covers document collection, test-license application and issuance, product manufacturing and testing, product approval, manufacturing-license application, regulatory evaluation and license issuance.
The process requires testing through accredited laboratories and regulatory evaluation based on manufacturing track record and a market-standing certificate. Avience does not state whether the proposed YEIDA facility has completed any of these stages, or whether test-license and final manufacturing-license applications have been submitted for its products.
January 2027 remains a target commissioning date, not a reported completion date. The presentation provides no construction-progress measure, machinery-procurement update, automation-installation schedule, production start date or capacity figure for the Rs 30.18 crore plant.
The customer ecosystem named by Avience includes government hospitals, private hospitals, diagnostic laboratories, healthcare institutions, research centres and distribution partners. However, it discloses no YEIDA-linked customer orders, analyzer contracts or demand forecasts, so the project’s commercial ramp-up is not quantified in the presentation.
Conclusion
Avience's expansion plan sets out a defined Rs 30.18 crore investment in a 2,100-square-metre automated factory dedicated to biochemistry analyzers. Compared with its earlier broad portfolio and manufacturing milestones from 2019 to 2025, the YEIDA project adds a specified site, funding structure and January 2027 commissioning target.
The next disclosed event to watch is the January 2027 commissioning target. Updates on deployment of Rs 15.95 crore in IPO proceeds, the Rs 12 crore SIDBI funding, factory execution and the CDSCO process, which Avience says averages 9 to 12 months, would clarify progress toward operations.


